| Year |
Citation |
Score |
| 2023 |
Pinto EM, Ribeiro EMSF, Wang J, Phillips AH, Kriwacki RW, Zambetti GP. Clinical and functional analysis of the germline TP53 p.K164E acetylation site variant. Cold Spring Harbor Molecular Case Studies. PMID 38050059 DOI: 10.1101/mcs.a006290 |
0.365 |
|
| 2023 |
Pinto EM, Fridman C, Figueiredo BC, Salvador H, Teixeira MR, Pinto C, Pinheiro M, Kratz CP, Lavarino C, Legal EAMF, Le A, Kelly G, Koeppe E, Stoffel EM, Breen K, ... ... Zambetti GP, et al. Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility. Hgg Advances. 5: 100244. PMID 37794678 DOI: 10.1016/j.xhgg.2023.100244 |
0.347 |
|
| 2023 |
Murphy AJ, Cheng C, Williams J, Shaw TI, Pinto EM, Dieseldorff-Jones K, Brzezinski J, Renfro LA, Tornwall B, Huff V, Hong AL, Mullen EA, Crompton B, Dome JS, Fernandez CV, ... ... Zambetti GP, et al. The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study. Research Square. PMID 36993649 DOI: 10.21203/rs.3.rs-2675436/v1 |
0.333 |
|
| 2021 |
Pinto EM, Rodriguez-Galindo C, Lam CG, Ruiz RE, Zambetti GP, Ribeiro RC. Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. Frontiers in Endocrinology. 12: 756523. PMID 34803919 DOI: 10.3389/fendo.2021.756523 |
0.321 |
|
| 2021 |
Jeffers JR, Pinto EM, Rehg JE, Clay MR, Wang J, Neale G, Heath RJ, Lozano G, Lalli E, Figueiredo BC, Pappo AS, Rodriguez-Galindo C, Chen W, Pounds S, Ribeiro RC, ... Zambetti GP, et al. The Common Germline TP53-R337H Mutation is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Research. PMID 33637564 DOI: 10.1158/0008-5472.CAN-20-1750 |
0.353 |
|
| 2020 |
Pinto EM, Zambetti GP. What 20 years of research has taught us about the TP53 p.R337H mutation. Cancer. PMID 32875577 DOI: 10.1002/cncr.33143 |
0.359 |
|
| 2020 |
Powers J, Pinto EM, Barnoud T, Leung JC, Martynyuk T, Kossenkov AV, Phillips AH, Desai H, Hausler R, Kelly G, Le AN, Li MM, MacFarland SP, Pyle LC, Zelley K, ... ... Zambetti GP, et al. A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers. Cancer Research. PMID 32675277 DOI: 10.1158/0008-5472.Can-20-1390 |
0.335 |
|
| 2020 |
Pinto EM, Faucz FR, Paza LZ, Wu G, Fernandes ES, Bertherat J, Stratakis CA, Lalli E, Ribeiro RC, Rodriguez-Galindo C, Figueiredo BC, Zambetti GP. Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors. Cancers. 12. PMID 32098292 DOI: 10.3390/cancers12020506 |
0.309 |
|
| 2019 |
Quinn EA, Maciaszek JL, Pinto EM, Phillips AH, Berdy D, Khandwala M, Upadhyaya SA, Zambetti GP, Kriwacki RW, Ellison DW, Nichols KE, Kesserwan C. From uncertainty to pathogenicity: Clinical and functional interrogation of a rare TP53 in-frame deletion. Cold Spring Harbor Molecular Case Studies. PMID 30886117 DOI: 10.1101/mcs.a003921 |
0.328 |
|
| 2018 |
Hu D, Jablonowski C, Cheng PH, AlTahan A, Li C, Wang Y, Palmer L, Lan C, Sun B, Abu-Zaid A, Fan Y, Brimble M, Gamboa N, Kumbhar RC, Yanishevski D, ... ... Zambetti GP, et al. KDM5A Regulates a Translational Program that Controls p53 Protein Expression. Iscience. 9: 84-100. PMID 30388705 DOI: 10.1016/j.isci.2018.10.012 |
0.386 |
|
| 2017 |
Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, Garfinkle EAR, Lam CG, Levy CF, Pappo AS, Zambetti GP, Ribeiro RC. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017742460. PMID 29058986 DOI: 10.1200/JCO.2017.74.2460 |
0.306 |
|
| 2016 |
Achatz MI, Zambetti GP. The Inherited p53 Mutation in the Brazilian Population. Cold Spring Harbor Perspectives in Medicine. PMID 27663983 DOI: 10.1101/cshperspect.a026195 |
0.37 |
|
| 2015 |
Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER, Wilson RK, Boggs K, Yergeau D, Cheng J, Mulder HL, Manne J, ... ... Zambetti GP, et al. Genomic landscape of paediatric adrenocortical tumours. Nature Communications. 6: 6302. PMID 25743702 DOI: 10.1038/ncomms7302 |
0.31 |
|
| 2014 |
Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Reports. 6: 271-7. PMID 24412360 DOI: 10.1016/J.Celrep.2013.12.020 |
0.427 |
|
| 2012 |
Lake BB, Fink J, Klemetsaune L, Fu X, Jeffers JR, Zambetti GP, Xu Y. Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma. Stem Cells (Dayton, Ohio). 30: 888-97. PMID 22311782 DOI: 10.1002/Stem.1054 |
0.314 |
|
| 2012 |
Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Molecular and Cellular Endocrinology. 351: 101-10. PMID 21930187 DOI: 10.1016/J.Mce.2011.09.010 |
0.43 |
|
| 2011 |
Zambetti GP. Diving into in vivo p53 tumor suppressor studies using a new platform mouse model. Cell Cycle (Georgetown, Tex.). 10: 2619. PMID 21841367 DOI: 10.4161/cc.10.16.16546 |
0.313 |
|
| 2011 |
Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (Georgetown, Tex.). 10: 2380-9. PMID 21709442 DOI: 10.4161/Cc.10.14.16588 |
0.302 |
|
| 2011 |
Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. Journal of Immunology (Baltimore, Md. : 1950). 187: 664-75. PMID 21690328 DOI: 10.4049/Jimmunol.1100029 |
0.355 |
|
| 2011 |
Kasper LH, Thomas MC, Zambetti GP, Brindle PK. Double null cells reveal that CBP and p300 are dispensable for p53 targets p21 and Mdm2 but variably required for target genes of other signaling pathways. Cell Cycle (Georgetown, Tex.). 10: 212-21. PMID 21220944 DOI: 10.4161/Cc.10.2.14542 |
0.362 |
|
| 2011 |
Zambetti GP, Ribeiro RC. TP53 molecular genetics Adrenocortical Carcinoma: Basic Science and Clinical Concepts. 193-205. DOI: 10.1007/978-0-387-77236-3_12 |
0.314 |
|
| 2010 |
Liu D, Ou L, Clemenson GD, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y. Puma is required for p53-induced depletion of adult stem cells. Nature Cell Biology. 12: 993-8. PMID 20818388 DOI: 10.1038/Ncb2100 |
0.303 |
|
| 2009 |
Phillips DC, Garrison SP, Jeffers JR, Zambetti GP. Assays to measure p53-dependent and -independent apoptosis. Methods in Molecular Biology (Clifton, N.J.). 559: 143-59. PMID 19609755 DOI: 10.1007/978-1-60327-017-5_11 |
0.352 |
|
| 2008 |
Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, Sample JT, Cleveland JL, Zambetti GP. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Molecular and Cellular Biology. 28: 5391-402. PMID 18573879 DOI: 10.1128/Mcb.00907-07 |
0.323 |
|
| 2006 |
West AN, Ribeiro RC, Jenkins J, Rodriguez-Galindo C, Figueiredo BC, Kriwacki R, Zambetti GP. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Research. 66: 5056-62. PMID 16707427 DOI: 10.1158/0008-5472.Can-05-4580 |
0.441 |
|
| 2006 |
Opferman JT, Zambetti GP. Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint Cell Death and Differentiation. 13: 898-901. PMID 16557265 DOI: 10.1038/Sj.Cdd.4401923 |
0.392 |
|
| 2006 |
Zambetti GP, Horwitz EM, Schipani E. Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development. The Journal of Cell Biology. 172: 795-7. PMID 16533941 DOI: 10.1083/jcb.200601114 |
0.324 |
|
| 2005 |
Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, Look AT. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell. 123: 641-53. PMID 16286009 DOI: 10.1182/Blood.V106.11.3624.3624 |
0.369 |
|
| 2005 |
Lozano G, Zambetti GP. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 8: 3-4. PMID 16023592 DOI: 10.1016/J.Ccr.2005.06.014 |
0.328 |
|
| 2005 |
Myers MC, Wang J, Iera JA, Bang JK, Hara T, Saito S, Zambetti GP, Appella DH. A new family of small molecules to probe the reactivation of mutant p53. Journal of the American Chemical Society. 127: 6152-3. PMID 15853303 DOI: 10.1021/Ja045752Y |
0.315 |
|
| 2005 |
Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? The Journal of Pathology. 205: 206-20. PMID 15643668 DOI: 10.1002/Path.1704 |
0.401 |
|
| 2003 |
Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 4: 321-8. PMID 14585359 DOI: 10.1016/S1535-6108(03)00244-7 |
0.346 |
|
| 2003 |
Kastan MB, Zambetti GP. Parc-ing p53 in the cytoplasm. Cell. 112: 1-2. PMID 12526785 DOI: 10.1016/S0092-8674(02)01281-3 |
0.33 |
|
| 2002 |
DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Structural Biology. 9: 12-6. PMID 11753428 DOI: 10.1038/Nsb730 |
0.35 |
|
| 2001 |
Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1 Oncogene. 20: 6983-6993. PMID 11704823 DOI: 10.1038/Sj.Onc.1204892 |
0.317 |
|
| 2001 |
Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth Gene. 277: 15-30. PMID 11602342 DOI: 10.1016/S0378-1119(01)00696-5 |
0.445 |
|
| 2001 |
Han JW, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals Proceedings of the National Academy of Sciences of the United States of America. 98: 11318-11323. PMID 11572983 DOI: 10.1073/Pnas.201208798 |
0.339 |
|
| 2001 |
Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD. Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1 Journal of Biological Chemistry. 276: 39359-39367. PMID 11483599 DOI: 10.1074/Jbc.M103429200 |
0.369 |
|
| 2001 |
Nip J, Strom DK, Eischen CM, Cleveland JL, Zambetti GP, Hiebert SW. E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation Oncogene. 20: 910-920. PMID 11314026 DOI: 10.1038/Sj.Onc.1204171 |
0.396 |
|
| 2001 |
Lecureur V, Thottassery JV, Sun D, Schuetz EG, Lahti J, Zambetti GP, Schuetz JD. Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo Oncogene. 20: 303-313. PMID 11313959 DOI: 10.1038/Sj.Onc.1204065 |
0.406 |
|
| 2000 |
Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes & Development. 14: 2358-65. PMID 10995391 DOI: 10.1101/Gad.827300 |
0.447 |
|
| 2000 |
Gu Z, Flemington C, Chittenden T, Zambetti GP. ei24, A p53 response gene involved in growth suppression and apoptosis Molecular and Cellular Biology. 20: 233-241. PMID 10594026 DOI: 10.1128/Mcb.20.1.233-241.2000 |
0.382 |
|
| 1998 |
Cadwell C, Zambetti GP. Regulators and mediators of the p53 tumor suppressor Journal of Cellular Biochemistry. Supplement. 30: 43-49. PMID 9893254 |
0.358 |
|
| 1998 |
Altura RA, Inukai T, Ashmun RA, Zambetti GP, Roussel MF, Look AT. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells. Blood. 92: 1397-405. PMID 9694729 |
0.358 |
|
| 1998 |
Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain Molecular and Cellular Biology. 18: 3735-3743. PMID 9632756 DOI: 10.1128/MCB.18.7.3735 |
0.412 |
|
| 1997 |
Momand J, Zambetti GP. Mdm-2: 'Big Brother' of p53 Journal of Cellular Biochemistry. 64: 343-352. PMID 9057092 DOI: 10.1002/(SICI)1097-4644(19970301)64:3<343::AID-JCB1>3.0.CO;2-V |
0.33 |
|
| 1997 |
Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor Molecular and Cellular Biology. 17: 389-397. PMID 8972219 DOI: 10.1128/Mcb.17.1.389 |
0.439 |
|
| 1996 |
Momand J, Zambetti GP. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics Oncogene. 12: 2279-2289. PMID 8649767 |
0.374 |
|
| 1993 |
Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53 Faseb Journal. 7: 855-865. PMID 8344485 DOI: 10.1096/fasebj.7.10.8344485 |
0.409 |
|
| 1992 |
Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element Genes and Development. 6: 1143-1152. PMID 1628822 DOI: 10.1101/Gad.6.7.1143 |
0.314 |
|
| 1992 |
Zambetti GP, Olson D, Labow M, Levine AJ. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs Proceedings of the National Academy of Sciences of the United States of America. 89: 3952-3956. PMID 1570319 DOI: 10.1073/pnas.89.9.3952 |
0.3 |
|
| 1992 |
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell. 69: 1237-1245. PMID 1535557 DOI: 10.1016/0092-8674(92)90644-R |
0.372 |
|
| Show low-probability matches. |